En Es
Categories

Industry News

QIAGEN Enters into Agreement to Acquire STAT-Dx

By Labmedica International staff writers
13 Feb 2018

Image: Qiagen plans to acquire diagnostics developer STAT-Dx for up to $191 million, in a deal designed to facilitate the buyer's planned launch later this year of the QIAstat-Dx platform, based on STAT-Dx’s proprietary DiagCORE technology (Photo courtesy of STAT-Dx).QIAGEN N.V. (The Netherlands) has entered into an agreement to acquire STAT-Dx (Barcelona, Spain), a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.

The system, which will be branded as QIAstat-Dx, enables scalable Sample to Insight processing of up to 48 molecular targets simultaneously for diagnosing syndromes, such as serious respiratory or gastrointestinal infections, as well as for use in oncology. With cost-efficient, easy-to-use assays suitable for any clinical sample type, the system can provide qualitative as well as quantitative insights into the precise cause of various syndromes in about one hour.

Based on the proprietary DiagCORE technology, the system received a first CE-IVD marking in January 2018. The system utilizes cost-efficient, single-use cartridges with built-in sample processing and all reagents on board. The cartridges are loaded with QIAGEN sample and assay technologies and a lab technician only needs to load a clinical sample into a cartridge and place it in the analyzer, requiring less than one minute of hands-on time.

The flexible modular system, which has bi-directional LIS (laboratory information system) interface capabilities, is designed to operate in a range of near-patient clinical settings, eliminating the delay of sending samples to a centralized laboratory. The cartridges are processed in a scalable, proprietary and fully integrated platform, which can be configured from one to eight modules, independently running cartridges with predefined assay protocols and managed via a touchscreen that offers simple step-by-step directions.

QIAstat-Dx is planned to be further developed with the aim of becoming the first analyzer that combines capabilities to run the highest multiplexing molecular diagnostic assays with the ability to quantitate and also process immunoassays. The first two tests, which are extensive respiratory and gastrointestinal (GI) panels, are to be launched in Europe in the second half of 2018, in the US in 2019 following regulatory clearance, and in other markets worldwide. Additional tests are under development for infectious diseases, immune response monitoring, oncology and companion diagnostics.

“QIAstat-Dx represents the next generation of innovation for multiplex syndromic testing, using powerful QIAGEN technologies and a real-time PCR technology that will allow for a much broader range of applications and drive the dissemination of molecular testing. The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment. Additional application areas for this system include companion diagnostics, quantitative analysis and immunoassay tests, offering customers a new level of flexibility and accurate diagnosis designed to support better outcomes for patients and healthcare systems,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “We look forward to adding QIAstat-Dx to our portfolio of Sample to Insight solutions. This is further confirmation as to how we are leveraging our advantages in sample and assay technologies, our leadership in providing solutions for infectious disease testing and the global reach of our commercial teams.”

“We are excited about accelerating the commercialization of our technology to bring fast, cost-effective syndromic testing closer to care for patients and healthcare providers. At the closing of the transaction, we will build on the achievements of our fantastic team in developing a best-in-class system and leverage QIAGEN’s resources with extensive R&D and commercial reach around the world,” said Jordi Carrera, co-founder and Chief Executive Officer of STAT-Dx.



E-mail Print
FaceBook Twitter Google+ Linked in

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Read More

Additional news

18 Oct 2018
Roche Launches Roche Healthcare Consulting
Roche (Basel, Switzerland) has launched Roche Healthcare Consulting, a specialized consulting service that aims to help leaders in laboratories, hospitals and other healthcare groups optimize their operational, clinical and financial performance.
Read More
18 Oct 2018
GE Healthcare and ESR Enter AI Partnership for ECR 2019
GE Healthcare (Chicago, IL, USA) and the European Society of Radiology (Vienna, Austria) will be partnering on artificial intelligence (AI) for the upcoming European Congress of Radiology (ECR) to be held in Vienna, Austria on February 27-March 3, 2019. The partnership will include joint sessions on AI and a dedicated space at GE Healthcare’s booth where visitors will be able to experience the AI transformation through interactive tools.
Read More
18 Oct 2018
AI-Based Approach Reduces False Positives in Mammography
A team of researchers from the University of Pittsburgh have developed an artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) that could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
Read More
18 Oct 2018
Global DR Detectors Market to Reach USD 2.7 Billion by 2026
The global digital radiography (DR) detectors market is projected to grow at a CAGR of 6.1% during 2018-2026 to reach a valuation of USD 2.71 billion by 2026, as an increase in the number of radiography tests performed each year, along with the introduction of new and advanced imaging equipment by key market players, drive the demand for DR detectors.
Read More
15 Oct 2018
AI Algorithm Uses Key Signatures to Predict Onset of AD
A team of researchers has designed an artificial intelligence (AI) algorithm that learns signatures from magnetic resonance imaging (MRI), genetics, and clinical data to accurately predict cognitive decline leading to Alzheimer’s disease. The algorithm can help predict whether an individual’s cognitive faculties are likely to deteriorate towards Alzheimer’s in the next five years.
Read More
15 Oct 2018
Breast Cancer Screening Machine Learning Software Receives CE Mark
A new deep learning-based breast cancer screening software has received the CE mark and will be launched within the UK’s National Health Service (NHS) and European healthcare systems. The software has been developed by Kheiron Medical Technologies, a start-up that combines novel deep learning methods, data science, and radiology expertise to enable diagnostics designed to detect cancers and improve patient outcomes.
Read More
15 Oct 2018
GE Healthcare to Implement First AI-Powered Hospital Command Centers
GE Healthcare is collaborating with hospital service providers in Europe and the US for implementing an artificial intelligence (AI)-powered command center to effectively and efficiently synchronize all elements of a patient's hospital experience. The AI-powered system will support caregivers to enhance patient safety, orchestrate seamless care delivery and get patients back home sooner.
Read More
11 Oct 2018
Scientists Use Machine Learning and MRI Scans to Predict Learning Difficulties
A team of scientists from the Medical Research Council (MRC) Cognition and Brain Sciences Unit at the University of Cambridge used machine learning - a type of artificial intelligence - with data from hundreds of children who struggle at school to identify clusters of learning difficulties, which did not match their previous diagnosis. According to the researchers, this reinforces the need for children to receive detailed assessments of their cognitive skills to identify the best type of support.
Read More
10 Oct 2018
Utilization of X-Ray Mammography Systems Expected to Increase
Over the last 20 years, hospitals and imaging centers in the developed economies have adopted X-ray mammography systems for the screening and diagnosis of breast cancer. This has resulted in a significant reduction in mortality and encouraged emerging countries to make investments in population-base, organized screening. These significant investments in mammography technology have paved the way for radiation safety, patient comfort and 3D imaging that enables precise tumor detection.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions